Business Wire

Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...
TechCrunch

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe’s Atomico and Silicon Valley-based R42. The company also ...
FierceBiotech

Healx raises $56M to launch 40 rare disease R&D programs

Healx has raised $56 million (€51 million) to launch 40 rare disease programs while taking some of its existing assets into the clinic. The ambitious target is enabled by an AI drug discovery platform ...
Finanznachrichten

Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De ...

Healx, the AI-powered biotech company pioneering the next generation of drug discovery for rare diseases, today announced it has entered into a strategic transaction with Vuja De Sciences, a US-based ...
Finanznachrichten

Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform

Healx will analyze proprietary Sanofi compound data using Healx's AI-driven drug discovery platform to generate therapeutic rationale Healx, an AI-enabled, clinical-stage biotech company specialising ...